We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Globe Life Trades Above 200-Day SMA: Time to Buy the Stock?
Read MoreHide Full Article
Key Takeaways
Globe Life revenues are rising on strong life and health premium growth and improving net investment income.
Globe Life expects solid 2026 sales growth across American Income, Liberty National and health segments.
Globe Life's strong liquidity and capital position support buybacks and a dividend raised 22.2% in Feb 2026.
Globe Life Inc. (GL - Free Report) has been trading above its 200-day simple moving average (SMA), signaling a short-term bullish trend. Its share price as of Wednesday was $138.80, down 9.1% from its 52-week high of $152.71.
The 200-day SMA is a long-term technical indicator that averages a stock's closing price over the last 200 trading days to smooth out volatility and identify the broader trend direction. When the stock price crosses above the 200-day SMA, it can be a signal to buy or hold.
Image Source: Zacks Investment Research
GL Shares are Affordable
Globe Life shares are trading at a discount compared to the industry. Its forward price-to-earnings multiple of 8.91X is lower than the industry average of 11.92X, the Finance sector’s 15.25X and the Zacks S&P 500 Composite’s 20.8X. Also, it has a Value Score of A.
Shares of other insurers like Unum Group (UNM - Free Report) are also trading at a discount to the industry average, while AMERISAFE, Inc. (AMSF - Free Report) and Aflac Incorporated (AFL - Free Report) are trading at a multiple.
Image Source: Zacks Investment Research
GL’s Price Performance
Globe Life shares have gained 5.6% in the past year against the industry’s decline of 4.7%.
Image Source: Zacks Investment Research
GL’s Growth Projection Encourages
The Zacks Consensus Estimate for Globe Life’s 2026 earnings per share indicates a year-over-year increase of 5.2%. The consensus estimate for 2025 revenues is pegged at $6.38 billion, implying a year-over-year improvement of 5.9%. The consensus estimate for 2027 earnings per share and revenues indicates an increase of 8.1% and 5.6%, respectively, from the corresponding 2026 estimates. Earnings have grown 16.1% in the past five years, better than the industry average of 0.6%.
Target Price Reflects Potential Upside
Based on short-term price targets offered by 12 analysts, the Zacks average price target is $170.50 per share. The average indicates a potential 23.99% upside from the last closing price.
Image Source: Zacks Investment Research
GL’s Return on Capital
GL’s trailing 12-month return on equity is 21.3%, ahead of the industry average of 14.3%. Return on equity, a profitability measure, reflects how effectively a company is utilizing its shareholders’ equity.
Also, the return on invested capital (ROIC) in the trailing 12 months was 12.6%, better than the industry average of 6.8%. Its ROIC has been increasing over the last few quarters amid capital investment made over the same time frame. This reflects the company’s efficiency in utilizing funds to generate income.
Key Points to Note for Globe Life
Globe Life has been witnessing a positive trend in revenues, driven by premium growth in its Life Insurance and Health Insurance segments and net investment income.
The strong performance of the American Income and Liberty National divisions should drive the top line in the future. Liberty National is likely to continue to benefit from improved productivity and agent count. GL’s expansion initiatives to capture heavily populated and less penetrated areas should drive growth in the future.
Globe Life expects net life sales of high single-digit growth at American Income, low double-digit growth at Liberty National, and mid-single digit growth at direct-to-consumer in 2026. The company expects Net health sales of low double-digit growth for both Liberty National and Family Heritage in 2026. For United American, the company is currently projecting flat sales growth for 2026.
Moreover, net investment income continues to be another important driver of the company’s top-line growth and has been exhibiting improvement over the last few years. The metric is likely to keep growing, riding on improved invested assets and higher interest rates on new investments.
The company has maintained a strong liquidity position with sufficient cash-generation capabilities. Its operations comprise writing basic protection life and supplemental health insurance policies, which generate strong and stable cash flows. For 2026, Global Life targets a consolidated company action level RBC ratio in the range of 300% to 320%.
A strong capital position enables Globe Life to enhance its shareholder value via share buybacks and dividend payouts. The insurer has also increased its dividend at a 9.2% CAGR from 2017 to 2026. In February 2026, it hiked its dividend by 22.2%
End Notes
Globe Life’s higher life and health sales, improved invested assets, increased productivity and agent count, strong liquidity position and effective capital deployment make it an attractive stock.
Its solid growth projections as well as attractive valuations are other positives. Coupled with a higher average price target and favorable return on capital, the time appears right for potential investors to bet on this Zacks Rank #2 (Buy) insurer. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Globe Life Trades Above 200-Day SMA: Time to Buy the Stock?
Key Takeaways
Globe Life Inc. (GL - Free Report) has been trading above its 200-day simple moving average (SMA), signaling a short-term bullish trend. Its share price as of Wednesday was $138.80, down 9.1% from its 52-week high of $152.71.
The 200-day SMA is a long-term technical indicator that averages a stock's closing price over the last 200 trading days to smooth out volatility and identify the broader trend direction. When the stock price crosses above the 200-day SMA, it can be a signal to buy or hold.
Image Source: Zacks Investment Research
GL Shares are Affordable
Globe Life shares are trading at a discount compared to the industry. Its forward price-to-earnings multiple of 8.91X is lower than the industry average of 11.92X, the Finance sector’s 15.25X and the Zacks S&P 500 Composite’s 20.8X. Also, it has a Value Score of A.
Shares of other insurers like Unum Group (UNM - Free Report) are also trading at a discount to the industry average, while AMERISAFE, Inc. (AMSF - Free Report) and Aflac Incorporated (AFL - Free Report) are trading at a multiple.
Image Source: Zacks Investment Research
GL’s Price Performance
Globe Life shares have gained 5.6% in the past year against the industry’s decline of 4.7%.
Image Source: Zacks Investment Research
GL’s Growth Projection Encourages
The Zacks Consensus Estimate for Globe Life’s 2026 earnings per share indicates a year-over-year increase of 5.2%. The consensus estimate for 2025 revenues is pegged at $6.38 billion, implying a year-over-year improvement of 5.9%. The consensus estimate for 2027 earnings per share and revenues indicates an increase of 8.1% and 5.6%, respectively, from the corresponding 2026 estimates.
Earnings have grown 16.1% in the past five years, better than the industry average of 0.6%.
Target Price Reflects Potential Upside
Based on short-term price targets offered by 12 analysts, the Zacks average price target is $170.50 per share. The average indicates a potential 23.99% upside from the last closing price.
Image Source: Zacks Investment Research
GL’s Return on Capital
GL’s trailing 12-month return on equity is 21.3%, ahead of the industry average of 14.3%. Return on equity, a profitability measure, reflects how effectively a company is utilizing its shareholders’ equity.
Also, the return on invested capital (ROIC) in the trailing 12 months was 12.6%, better than the industry average of 6.8%. Its ROIC has been increasing over the last few quarters amid capital investment made over the same time frame. This reflects the company’s efficiency in utilizing funds to generate income.
Key Points to Note for Globe Life
Globe Life has been witnessing a positive trend in revenues, driven by premium growth in its Life Insurance and Health Insurance segments and net investment income.
The strong performance of the American Income and Liberty National divisions should drive the top line in the future. Liberty National is likely to continue to benefit from improved productivity and agent count. GL’s expansion initiatives to capture heavily populated and less penetrated areas should drive growth in the future.
Globe Life expects net life sales of high single-digit growth at American Income, low double-digit growth at Liberty National, and mid-single digit growth at direct-to-consumer in 2026. The company expects Net health sales of low double-digit growth for both Liberty National and Family Heritage in 2026. For United American, the company is currently projecting flat sales growth for 2026.
Moreover, net investment income continues to be another important driver of the company’s top-line growth and has been exhibiting improvement over the last few years. The metric is likely to keep growing, riding on improved invested assets and higher interest rates on new investments.
The company has maintained a strong liquidity position with sufficient cash-generation capabilities. Its operations comprise writing basic protection life and supplemental health insurance policies, which generate strong and stable cash flows. For 2026, Global Life targets a consolidated company action level RBC ratio in the range of 300% to 320%.
A strong capital position enables Globe Life to enhance its shareholder value via share buybacks and dividend payouts. The insurer has also increased its dividend at a 9.2% CAGR from 2017 to 2026. In February 2026, it hiked its dividend by 22.2%
End Notes
Globe Life’s higher life and health sales, improved invested assets, increased productivity and agent count, strong liquidity position and effective capital deployment make it an attractive stock.
Its solid growth projections as well as attractive valuations are other positives. Coupled with a higher average price target and favorable return on capital, the time appears right for potential investors to bet on this Zacks Rank #2 (Buy) insurer. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.